Stipple Bio, Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Biotech
- Headquarters
- Cambridge, MA
- Street
- 238 Main Street
- Zip
- 02142
Offering
- Total offering
- $100.2M
- Amount sold
- $65.1M
- First sale
- Mar 31, 2026
- Min investment
- $0
- Securities
- Equity
- Federal exemption
- Rule 506(b)
- Investors so far
- 15
How this filing compares
Ranked #3 of 47 Biotech filings in April 2026 by offering amount.
Median Biotech filing in April 2026: $3M. This offering is 33.4× the median.
Other Massachusetts filings this week: 4Mission Capital, LLC, ACCAF LTH LLC, CA Select Co-Investments 2024 (Cayman Feeder), LP, CA Select Co-Investments 2024, LP, CA Velocity Fund (Cayman Feeder), LP
Leadership
Jeffrey Landau — Executive Officer (also: Director)
Vineeta Agarwala — Director
Owen Hughes — Director
Greg Verdine — Director
Aaron Ring — Director
Derek DiRocco — Director
Thilo Schroeder — Director
Filing details
Stipple Bio, Inc. filed a Form D with the SEC on April 6, 2026.